327 related articles for article (PubMed ID: 27381850)
41. Blood circulating miRNAs as biomarkers of Alzheimer's disease: a systematic review and meta-analysis.
Zhang YH; Bai SF; Yan JQ
Biomark Med; 2019 Aug; 13(12):1045-1054. PubMed ID: 31385521
[No Abstract] [Full Text] [Related]
42. Evaluation of the Common Molecular Basis in Alzheimer's and Parkinson's Diseases.
Rana P; Franco EF; Rao Y; Syed K; Barh D; Azevedo V; Ramos RTJ; Ghosh P
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31366155
[TBL] [Abstract][Full Text] [Related]
43. MicroRNAs in the pathophysiology of Alzheimer's disease and Parkinson's disease: an overview.
Khezri MR; Yousefi K; Zolbanin NM; Ghasemnejad-Berenji M
Mol Neurobiol; 2022 Mar; 59(3):1589-1603. PubMed ID: 35001356
[TBL] [Abstract][Full Text] [Related]
44. Cerebrospinal Fluid Biomarkers for Target Engagement and Efficacy in Clinical Trials for Alzheimer's and Parkinson's Diseases.
Parnetti L; Eusebi P; Lleó A
Front Neurol Neurosci; 2016; 39():117-23. PubMed ID: 27463974
[TBL] [Abstract][Full Text] [Related]
45. Dysregulated miRNAs as Biomarkers and Therapeutical Targets in Neurodegenerative Diseases.
Gentile G; Morello G; La Cognata V; Guarnaccia M; Conforti FL; Cavallaro S
J Pers Med; 2022 May; 12(5):. PubMed ID: 35629192
[TBL] [Abstract][Full Text] [Related]
46. Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases.
Williams SM; Schulz P; Sierks MR
Eur J Neurosci; 2016 Jan; 43(1):3-16. PubMed ID: 26332448
[TBL] [Abstract][Full Text] [Related]
47. Preliminary Study of hsa-mir-626 Change in the Cerebrospinal Fluid in Parkinson's Disease.
Qin LX; Tan JQ; Zhang HN; Tang JG; Jiang B; Shen XM; Guo JF; Tan LM; Tang B; Wang CY
Neurol India; 2021; 69(1):115-118. PubMed ID: 33642281
[TBL] [Abstract][Full Text] [Related]
48. Blood serum miRNA: non-invasive biomarkers for Alzheimer's disease.
Geekiyanage H; Jicha GA; Nelson PT; Chan C
Exp Neurol; 2012 Jun; 235(2):491-6. PubMed ID: 22155483
[TBL] [Abstract][Full Text] [Related]
49. Role of microRNAs in neurodegeneration induced by environmental neurotoxicants and aging.
Singh T; Yadav S
Ageing Res Rev; 2020 Jul; 60():101068. PubMed ID: 32283224
[TBL] [Abstract][Full Text] [Related]
50. microRNAs and Neurodegenerative Diseases.
Qiu L; Tan EK; Zeng L
Adv Exp Med Biol; 2015; 888():85-105. PubMed ID: 26663180
[TBL] [Abstract][Full Text] [Related]
51. Serum alpha 1-antichymotrypsin is not a useful marker for Alzheimer's disease or dementia in Parkinson's disease.
Kuiper MA; van Kamp GJ; Bergmans PL; Scheltens P; Wolters EC
J Neural Transm Park Dis Dement Sect; 1993; 6(2):145-9. PubMed ID: 8117411
[TBL] [Abstract][Full Text] [Related]
52. Erythrocyte thiolmethyltransferase: another failed marker for Alzheimer's and Parkinson's diseases.
Hurwitz A; Hubble JP; Glatt SL; Koller WC; Pollack J
Neurology; 1995 Oct; 45(10):1903-6. PubMed ID: 7477990
[TBL] [Abstract][Full Text] [Related]
53. Using cerebrospinal fluid marker profiles in clinical diagnosis of dementia with Lewy bodies, Parkinson's disease, and Alzheimer's disease.
Kaerst L; Kuhlmann A; Wedekind D; Stoeck K; Lange P; Zerr I
J Alzheimers Dis; 2014; 38(1):63-73. PubMed ID: 23948928
[TBL] [Abstract][Full Text] [Related]
54. Increases of pentraxin 3 plasma levels in patients with Parkinson's disease.
Lee HW; Choi J; Suk K
Mov Disord; 2011 Nov; 26(13):2364-70. PubMed ID: 21953577
[TBL] [Abstract][Full Text] [Related]
55. Validating Alzheimer's disease micro RNAs using next-generation sequencing.
Keller A; Backes C; Haas J; Leidinger P; Maetzler W; Deuschle C; Berg D; Ruschil C; Galata V; Ruprecht K; Stähler C; Würstle M; Sickert D; Gogol M; Meder B; Meese E
Alzheimers Dement; 2016 May; 12(5):565-76. PubMed ID: 26806387
[TBL] [Abstract][Full Text] [Related]
56. Circulating miRNAs: a new generation of anti-doping biomarkers.
Leuenberger N; Robinson N; Saugy M
Anal Bioanal Chem; 2013 Dec; 405(30):9617-23. PubMed ID: 24077830
[TBL] [Abstract][Full Text] [Related]
57. Epigenetics in Parkinson's and Alzheimer's diseases.
Marques S; Outeiro TF
Subcell Biochem; 2013; 61():507-25. PubMed ID: 23150265
[TBL] [Abstract][Full Text] [Related]
58. MicroRNA‑34a‑5p expression in the plasma and in its extracellular vesicle fractions in subjects with Parkinson's disease: An exploratory study.
Grossi I; Radeghieri A; Paolini L; Porrini V; Pilotto A; Padovani A; Marengoni A; Barbon A; Bellucci A; Pizzi M; Salvi A; De Petro G
Int J Mol Med; 2021 Feb; 47(2):533-546. PubMed ID: 33416118
[TBL] [Abstract][Full Text] [Related]
59. Ultrasensitive detection of blood biomarkers of Alzheimer's and Parkinson's diseases: a systematic review.
Singh K; Cheung BM; Xu A
Biomark Med; 2021 Dec; 15(17):1693-1708. PubMed ID: 34743546
[No Abstract] [Full Text] [Related]
60. The Impact of Dysregulated microRNA Biogenesis Machinery and microRNA Sorting on Neurodegenerative Diseases.
Weng YT; Chang YM; Chern Y
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
